| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study. |
| 掲載誌名 | 正式名：Allergology international : official journal of the Japanese Society of Allergology 略 称：Allergol Int ISSNコード：14401592/13238930 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Minami Koriyama, Yoshitaka Okamoto, Tomoya Kurokawa, Tatsuya Noda, Yasuyuki Okumura, Daiju Sakurai, Mitsuhiro Okano, Yasushi Suwazono, Tomohisa Iinuma, Toyoyuki Hanazawa, Yuichi Nishioka, Tomoya Myojin, Tomoaki Imamura, Syuji Yonekura |
| 発行年月 | 2026/07 |
| 概要 | BACKGROUND:Allergic rhinitis (AR) prevalence is increasing worldwide. However, while information on the economic burden of AR remains limited globally, nationwide data for Japan are similarly scarce. Therefore, we investigated healthcare utilization and prescription drug costs for seasonal AR using a nationwide claims database, primarily focusing on spring AR.METHODS:This observational study used the National Database of Health Insurance Claims (2018-2019). Patients with spring AR were defined as those with an AR-related diagnosis and prescriptions covering ≥14 days in each of the two spring pollen seasons (January-April) in 2018 and 2019 (pre-COVID-19 years with heavy pollen dispersal). Patients with summer (May-August) and autumn (September-December) AR were similarly identified, whereas patients with perennial-only AR were excluded. We calculated the number of patients, healthcare visits, drug costs, and the correlation between the number of spring AR patients and pollen counts.RESULTS:Spring AR involved 12.9 million patients (female-to-male ratio, 1.36), with annual prescription drug costs of 101.8 billion yen (7874 yen per patient), a mean of 3.05 visits per season, and 83% of patients visiting outpatient clinics without beds. Regional patient numbers were correlated with pollen counts (Spearman's r = 0.61). Summer and autumn AR involved 5.7 million and 6.1 million patients, with costs of 38.7 and 42.4 billion yen, respectively.CONCLUSIONS:Patients with seasonal AR identified using strict criteria totaled 24.7 million annually, with drug costs totaling 182.9 billion yen. These figures represent a conservative estimate of the minimum medical expenditure for seasonal AR in Japan. |
| DOI | 10.1016/j.alit.2026.06.004 |
| PMID | 42538191 |